Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369: 2106-2120
Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4: 253-265
Vermeulen K, Berneman ZN, Van Bockstaele DR. Cell cycle and apoptosis. Cell Prolif 2003; 36: 165-175
Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011; 471: 110-114
Harley ME, Allan LA, Sanderson HS, Clarke PR. Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J 2010; 29: 2407-2420
Frankland-Searby S, Bhaumik SR. The 26S proteasome complex: An attractive target for cancer therapy. Biochim Biophys Acta 2012; 1825: 64-76
Voorhees PM, Orlowski RZ. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 2006; 46: 189-213
de Wilt LH, Kroon J, Jansen G, de Jong S, Peters GJ, Kruyt FA. Bortezomib and TRAIL: A perfect match for apoptotic elimination of tumour cells? Crit Rev Oncol Hematol 2013; 85: 363-372
Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M, et al. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 2006; 98: 1142-1157
Khan T, Stauffer JK, Williams R, Hixon JA, Salcedo R, Lincoln E, et al. Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors. J Immunol 2006; 176: 6302-6312
Hamner JB, Dickson PV, Sims TL, Zhou J, Spence Y, Ng CY, et al. Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma. Surgery 2007; 142: 185-191
Combaret V, Boyault S, Iacono I, Brejon S, Rousseau R, Puisieux A. Effect of bortezomib on human neuroblastoma: Analysis of molecular mechanisms involved in cytotoxicity. Mol Cancer 2008; 7: 50
Armstrong MB, Schumacher KR, Mody R, Yanik GA, Opipari AW Jr, Castle VP. Bortezomib as a therapeutic candidate for neuroblastoma. J Exp Ther Oncol 2008; 7: 135-145
Michaelis M, Fichtner I, Behrens D, Haider W, Rothweiler F, Mack A, et al. Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. Int J Oncol 2006; 28: 439-446
Valentiner U, Haane C, Nehmann N, Schumacher U. Effects of bortezomib on human neuroblastoma cells in vitro and in a metastatic xenograft model. Anticancer Res 2009; 29: 1219-1225
Naumann I, Kappler R, von Schweinitz D, Debatin KM, Fulda S. Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway. Clin Cancer Res 2011; 17: 3204-3218
Unterkircher T, Cristofanon S, Vellanki SH, Nonnenmacher L, Karpel-Massler G, Wirtz CR, et al. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin Cancer Res 2011; 17: 4019-4030
Tamura D, Arao T, Tanaka K, Kaneda H, Matsumoto K, Kudo K, et al. Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition. Cancer Sci 2010; 101: 1403-1408
Strebhardt K. Multifaceted polo-like kinases: Drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010; 9: 643-660
Hans F, Dimitrov S. Histone H3 phosphorylation and cell division. Oncogene 2001; 20: 3021-3027
Janssen A, Medema RH. Mitosis as an anti-cancer target. Oncogene 2011; 30: 2799-2809
Lu Z, Hunter T. Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors. Cell Cycle 2010; 9: 2342-2352
Deng X, Gao F, Flagg T, May WS Jr. Mono-And multisite phosphorylation enhances Bcl2's antiapoptotic function and inhibition of cell cycle entry functions. Proc Natl Acad Sci USA 2004; 101: 153-158
Willimott S, Wagner SD. Post-Transcriptional and post-Translational regulation of Bcl2. Biochem Soc Trans 2010; 38: 1571-1575
Deng X, Gao F, May WS Jr. Bcl2 retards G1/S cell cycle transition by regulating intracellular ROS. Blood 2003; 102: 3179-3185
Mazel S, Burtrum D, Petrie HT. Regulation of cell division cycle progression by bcl-2 expression: A potential mechanism for inhibition of programmed cell death. J Exp Med 1996; 183: 2219-2226
Vega MI, Martinez-Paniagua M, Jazirehi AR, Huerta-Yepez S, Umezawa K, Martinez-Maza O, et al. The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximabresistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. Leuk Lymphoma 2008; 49: 1982-1994
Dong QG, Sclabas GM, Fujioka S, Schmidt C, Peng B, Wu T, et al. The function of multiple IkappaB: NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 2002; 21: 6510-6519
Bruning A, Burger P, Vogel M, Rahmeh M, Friese K, Lenhard M, et al. Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis. Invest New Drugs 2009; 27: 543-551
Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 5025-5033
Loeder S, Fakler M, Schoeneberger H, Cristofanon S, Leibacher J, Vanlangenakker N, et al. RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. Leukemia 2012; 26: 1020-1029
Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57: 3823-3829
Hacker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S, Krauss J, et al. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 2009; 28: 3097-3110
Chou TC. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC (ed). Synergism and Antagonism in Chemotherapy. Academic Press: San Diego, CA, USA, 1991. pp 61-102
